A phase III study of trans sodium crocetinate (TSC) in combination with radiation and/or chemotherapy in patients with newly diagnosed with glioblastoma multiforme (GBM).

Trial Profile

A phase III study of trans sodium crocetinate (TSC) in combination with radiation and/or chemotherapy in patients with newly diagnosed with glioblastoma multiforme (GBM).

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Transcrocetinate sodium (Primary)
  • Indications Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Diffusion Pharmaceuticals
  • Most Recent Events

    • 06 Jul 2017 This trial is expected to be initiated in the end of 2017, according to a Diffusion Pharmaceuticals media release.
    • 08 Jun 2016 According to a Diffusion Pharmaceuticals media release, the U.S. Food and Drug Administration has agreed upon the design of this Phase 3 trial in newly diagnosed GBM.
    • 08 Jun 2016 Status changed from planning to not yet recruiting, according to a Diffusion Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top